P068 NATALIZUMAB MAINTAINS REMISSION FOR 2 YEARS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND IN THOSE WITH PRIOR INFLIXIMAB EXPOSURE: RESULTS FROM AN OPEN-LABEL EXTENSION STUDY | Zendy

AI Assistant Blog Pricing

P068 NATALIZUMAB MAINTAINS REMISSION FOR 2 YEARS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND IN THOSE WITH PRIOR INFLIXIMAB EXPOSURE: RESULTS FROM AN OPEN-LABEL EXTENSION STUDY

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.